Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

SQI Diagnostics Inc V.SQD.H

SQI Diagnostics Inc. is a Canada-based company that is focused on lung health. The Company is engaged in the development and manufacturing of respiratory health and precision medicine tests that run on its fully automated systems. Its clinical solutions include Rapid Acute Lung Injury Diagnostic (RALI-Dx), lung transplant diagnostics, COVID-19 testing and surveillance testing solutions. Its RALI-Dx IL-6 Severity Triage Test and the RALI-fast IL-6 Severity Triage point of care (POC) Test each help clinicians identify which patients with SARS-CoV-2 are predicted to have a severe inflammatory response and should or should not be admitted to the hospital. Its RALI-Dx delivers results from the lab in less than an hour while RALI-fast delivers results at the patient point-of-care in about 15 minutes. The Company’s TORdx LUNG Test measures inflammation at the molecular level to assess the health of the donor lung. The Company is also focused on its organ transplant pipeline of products.


TSXV:SQD.H - Post by User

Post by FactFinder1994on Feb 27, 2023 7:24pm
122 Views
Post# 35308423

Commercialization at UHN - LinkedIn Post last week

Commercialization at UHN - LinkedIn Post last weekExciting news today from the office of the Hon. Franois-Philippe Champagne meaningful to life science commercialization!  

Enabling and leading commercialization and industry partnerships for a healthier world, Commercialization at UHN is the catalyst for accelerating University Health Network’s world-class research discoveries towards maximum patient impact globally, bringing commercially viable technologies to market to create A Healthier World. 

Medical technologies discovered, developed and de-risked at UHN form the basis of products and services improving health care for patients internationally, including therapeutics, devices and diagnostics and in many cases, these represent the foundational platforms for a number of successful companies first incubated within UHN and the Toronto ecosystem, with a wide economic footprint.  

As Canada's medical research commercialization leader, the University Health Network has a robust pipeline of new ventures and formed companies that stand to benefit from such focused investment for years to come. View our growing new ventures pipeline here: https://bit.ly/3I0LMes

Read the federal news release here: https://bit.ly/3XHrH1x

RE:  https://lnkd.in/gHNHWeXB

Franois-Philippe Champagne Chrystia Freeland Victor Fedeli Brad Wouters Mark Taylor Bharti Ranavaya University Health Network Research at UHN 

                                                                   Ottawa launches funding agency to help commercialize research, protect intellectual property theglobeandmail.com • 5 min read                                                    
<< Previous
Bullboard Posts
Next >>